Key result
Patients in the highest tertile of B-type natriuretic peptide had a significantly higher risk of 3-year all-cause mortality compared to those in the lowest tertile (adjusted HR 4.18).
Why the study?
The association between B-type natriuretic peptide levels and long-term mortality in patients with acute severe hypertension visiting the emergency department remains unclear.
Does elevated B-type natriuretic peptide (BNP) predict 3-year all-cause mortality in adults with acute severe hypertension visiting the emergency department?
Cohort (n=3,099)
No
Does elevated B-type natriuretic peptide (BNP) predict 3-year all-cause mortality in adults with acute severe hypertension visiting the emergency department?
Elevated BNP levels upon emergency department admission independently predict long-term all-cause mortality in patients with acute severe hypertension, suggesting its utility for risk stratification.
B-type natriuretic peptide (BNP) is a well-established prognostic factor for cardiovascular disorders. However, the association between BNP levels and mortality in patients with acute severe hypertension remains unclear. This study aimed to investigate the association between BNP levels and long-term mortality in patients with acute severe hypertension visiting the emergency department (ED). This retrospective study included patients aged ≥ 18 years who were admitted to the ED between 2016 and 2019 with acute severe hypertension (systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 100 mmHg). Patients were categorized into tertiles according to BNP levels upon admission to the ED. Of the 3099 patients with acute severe hypertension, 6.4% in the first (lowest) tertile, 24.8% in the second tertile, and 44.4% in the third (highest) tertile of BNP died within 3-years. After adjusting for clinically relevant variables, patients in the second tertile of BNP (adjusted hazard ratio [HR], 2.64; 95% confidence interval [CI], 1.96-3.55), and patients in the third tertile of BNP (adjusted HR 4.18; 95% CI, 3.09-5.64) had a significantly higher risk of 3-year all-cause mortality than those in the first tertile of BNP. Therefore, BNP may be valuable for the initial assessment to identify high-risk patients among those with acute severe hypertension.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2022) conducted a cohort in Acute severe hypertension (n=3,099). B-type natriuretic peptide (BNP) levels vs. Lowest tertile of BNP (≤ 37 pg/mL) was evaluated on 3-year all-cause mortality (HR 4.18, 95% CI 3.09-5.64, p=<0.001). Patients in the highest tertile of B-type natriuretic peptide had a significantly higher risk of 3-year all-cause mortality compared to those in the lowest tertile (adjusted HR 4.18).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: